Objective: Sleep laboratory study to determine the dose-related efficacy and safety of almorexant in elderly patients with primary chronic insomnia. Methods: Patients aged ≥65 years with primary insomnia were enrolled into a prospective, randomized, double-blind, placebo-controlled, multicenter dose-finding study with a five-period, five-way Latin square cross-over design. Patients were randomized to one of 10 unique sequences of two-night treatment with oral almorexant 25, 50, 100, or 200 mg capsules, or matching placebo. The primary efficacy endpoint was polysomnography (PSG)-determined mean wake time after sleep onset (WASO). Secondary and exploratory efficacy endpoints were also assessed. No unexpected safety concerns were identified. Adverse events were similar between all almorexant dose groups and placebo. Conclusions: Two-night oral administration of almorexant was effective and well tolerated in treating primary insomnia in elderly patients.
INTRODUCTION
Insomnia is a chronic disorder that can occur in isolation (ie, primary) or comorbid with other chronic physical and psychiatric conditions, including arthritis, cardiovascular disease, diabetes, and depression. 1, 2 Chronic primary insomnia is generally defined as difficulty initiating or maintaining sleep, or nonrestorative sleep for ≥1 month, accompanied by significant distress and daytime impairment. [2] [3] [4] [5] Sufferers may have trouble getting to sleep, awake frequently with difficulty getting back to sleep, or feel unrefreshed, or experience a combination of these symptoms. 3, 6 Consequently, insomnia has a negative impact on the quality of life and day-to-day functioning. 2, 4 Disturbed sleep has been estimated to affect 30%-40% of adults each year, 7 with up to 20% of those affected having chronic insomnia. 2 It is approximately 1.5 times more frequent in women than in men, and around 33% of all people aged over 65 years report having disturbed sleep. 2, [6] [7] [8] [9] Although acute emotional stress can induce disturbed sleep, many people diagnosed with chronic insomnia suffer from physiological hyperarousal, which leads to insomnia. 10, 11 Significant physiological differences have been found between good and poor sleepers. Altered electroencephalographic (EEG) alpha/ beta activity, abnormal hormone secretion, increased metabolic activation, and raised heart rate have been observed during sleep in patients with primary insomnia, possibly linked to increased sympathetic nervous system activity and hypothalamic-pituitary-adrenal axis activation. 10, 11 Reduction of arousal represents a potential therapeutic approach for the treatment of insomnia.
Sedative-hypnotic medications are the mainstays of pharmacological treatment for insomnia. GABAergic drugs, specifically the benzodiazepines (eg, temazepam) and "non-benzodiazepine" hypnotics (eg, zopiclone, zolpidem, or zaleplon) are commonly used. However, all of the GABAergic hypnotics come with a degree of risk for adverse effects including cognitive impairment, residual next-day effects, psychomotor effects, and daytime sleepiness, especially at higher doses, and among those with longer durations of action. 12 Misuse and/or abuse can occur in at-risk individuals.
The melatonin receptor agonist, ramelteon, is also approved for the treatment of insomnia, but confers relatively modest improvements on sleep onset, and little or no effect on sleep maintenance. 13 There is therefore an ongoing need for treatments that promote sleep maintenance without residual nextday sedation or other adverse effects.
Over the last decade, accrued knowledge of orexin A and orexin B, which are synthesized in the perifornical and lateral hypothalamic neurons in the brain, have revealed important roles for these excitatory neuropeptides in maintaining wakefulness, regulating arousal, and maintaining sleep-wake balance.
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Statement of Significance
Over the last decade, accrued knowledge of orexins A and B has revealed important roles for these excitatory neuropeptides in maintaining wakefulness, regulating arousal, and maintaining sleep-wake balance. Almorexant is an orally active, selective, competitive dual orexin receptor antagonist that has demonstrated favorable safety/tolerability and relevant pharmacodynamic effects on sleep measures in healthy adult and elderly subjects. This study revealed dose-related efficacy of almorexant in elderly patients with primary insomnia using both objective (polysomnographic) and patient-reported measures. These results add to existing evidence indicating that reducing endogenous orexin activity may be a useful therapeutic approach for chronic insomnia. Further studies are required to confirm the efficacy of orexin-inhibiting agents for the treatment of insomnia in wider patient populations.
regions associated with the regulation of sleep-wake systems. 18 The orexin system maintains alertness and it has been hypothesized that it may also mediate unwanted wakefulness in insomnia. 19 This formed the basis for developing drugs targeting orexin receptors. 17 Subsequently, several dual orexin receptor antagonists (DORAs) that inhibit both OX 1 R and OX 2 R have been developed. 17, 19, 20 Suvorexant is the first such agent to be approved for the treatment of insomnia, and has been reported to be effective and well tolerated during randomized placebo-controlled trials. 21 Almorexant (Actelion Pharmaceuticals Ltd, Switzerland) is an orally active, selective, competitive DORA that has been shown to have 600-fold greater affinity for orexin receptors compared with other common receptors and enzymes, including benzodiazepine, GABA-A, opiate, adenosine, and histamine receptors. Phase I trials identified favorable safety/tolerability and relevant pharmacodynamic effects on sleep measures in healthy adult and elderly subjects. [22] [23] [24] [25] A proof-of-concept/dose-finding study in 161 adults with primary insomnia showed significantly improved mean sleep efficiency following a single dose of almorexant 400 mg compared with placebo (85% vs. 71%, respectively; p < .0001). 26 Significant and dose-related reductions in mean wake time after sleep onset (WASO; -54.0 minutes vs. placebo) and reduced mean latency to persistent sleep (LPS; -18 minutes vs. placebo) were also observed.
The present study was conducted to evaluate the effects of a two-night oral administration of almorexant across a range of doses on WASO, LPS, total sleep time (TST), sleep architecture and next-day performance, and to assess safety and tolerability, in elderly patients with primary insomnia.
METHODS

Patients
Men and women with primary insomnia (as defined by DSM-IV TR 5 ) aged ≥65 years and with a body mass index (BMI) ≥ 18.5 and < 34 kg/m 2 were enrolled. Eligible patients had a subjective TST < 6 hours, subjective time to fall asleep ≥ 30 minutes, and daytime complaints associated with poor sleep during the previous 3 months, as well as polysomnography (PSG)-assessed mean WASO ≥ 45 minutes (with neither night < 30 minutes), mean TST ≥ 240 and < 390 minutes (with neither night ≥ 420 minutes), and mean LPS ≥ 20 minutes (with neither night < 15 minutes) during two screening PSG assessments.
Patients with a history of any other sleep disorder or current axis-I psychiatric disorder other than primary insomnia (DSM-IV-TR 5 ), depression within the past 6 months, or an apnea/hypopnea index (AHI) ≥ 15/h on the first PSG screening night were excluded. Those with a periodic limb movement arousal index (PLMAI) ≥ 15/h on the first PSG screening night, usual daytime napping ≥ 1 h/d and ≥ 3 d/wk, or significant caffeine consumption ( ≥ 500 mg/d) were also excluded. Shift work within 6 months of screening, drug or alcohol abuse within 2 years of screening, or a history of circadian rhythm disorders also led to exclusion.
Non-pharmacological treatments for insomnia were allowed if started ≥1 month prior to the screening visit and stable until 24 hours after the last administration of study treatment. CNSactive drugs were prohibited.
The study was approved by all responsible independent ethics committees, and was conducted according to the International Conference on Harmonization guidelines on good clinical practice, the Code of Federal Regulations, and the Declaration of Helsinki. Written informed consent was obtained from the patients. Patients were reimbursed for their participation.
Study Design
This was a multicenter, double-blind, randomized, placebo-controlled, five-period, five-way cross-over, dose-finding study. Overall, the study comprised a 2-to 4-week screening phase, a 4-to 8-week treatment phase (including the five treatment periods), and a 28-day safety follow-up.
The screening visit was followed by completion of a sleep diary at home every day for 7 consecutive days to collect self-reported information on sleep induction and maintenance, as well as habitual bedtime and frequency of napping. After this 7-day period eligible patients participated in two consecutive PSG screening nights during which they received single-blind placebo.
Eligible patients were randomized to one of 10 unique sequences, from among a possible 120 combinations, of five 2-day treatments (almorexant 25, 50, 100 and 200 mg, and matching placebo) according to a Williams Latin square design. Randomization was conducted centrally 5-12 days after the second PSG screening by InterActive Voice Response Services (Covance IVRS, Princeton, USA) according to a central randomization list generated using SAS PROC PLAN. Each treatment period consisted of two consecutive PSG nights, and was separated from other treatment periods by a 5-12 day washout. Study medication was administered orally in a double-blind manner in the evening, 30 minutes before "lights out" (start of the PSG recording) on two consecutive nights.
Study Assessments
Objective sleep parameters were based on PSG recordings according to standardized methods, 27 with the time in bed fixed at 480 minutes. The first screening PSG recording started within 30 minutes of patients' usual bed time, and this time was held constant throughout the study. PSG recordings were scored centrally and blinded in relation to treatment.
Following each PSG recording, a morning questionnaire assessed self-reported sleep characteristics and alertness. A questionnaire completed on the second PSG evening before study drug administration assessed functioning and alertness since leaving the laboratory after the first PSG night. Both the morning and evening questionnaires utilized a 100 mm visual analog scale (VAS). Each morning the profile of mood state (POMS) questionnaire was administered, which assesses six mood factors including tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment, scored according to a 5-point scale. The Digit Symbol Substitution Test (DSST) was used to measure residual effects the morning after each PSG. 28 
Efficacy Endpoints
The primary efficacy endpoint was mean WASO (in minutes), defined as the time spent awake between the onset of persistent sleep and "lights on": the onset of persistent sleep was defined as the first epoch of 10 minutes of continuous sleep. Secondary efficacy endpoints were mean TST and mean LPS. A number of exploratory efficacy measures were also assessed, including mean WASO by quarter and by hour of the night, sleep architecture, self-reported sleep characteristics from the morning questionnaire, and next-day performance and alertness (Supplementary Table S1 ).
Safety and Tolerability
Safety endpoints included adverse events (AEs) up to 72 hours after the last dose of study medication, serious AEs (SAEs) up to 28 days after treatment, AEs leading to premature discontinuation of study treatment, clinical laboratory abnormalities, hormone concentrations (cortisol, adrenocorticotropic hormone, follicle stimulating hormone, thyroxine, ghrelin, leptin, luteinizing hormone, prolactin, testosterone, and dehydroepiandrosterone) electrocardiogram (ECG) abnormalities, vital signs, and DSST.
Statistical Analysis
The null hypothesis was that there was no difference between any dose of almorexant and placebo (tested hierarchically from 200 to 25 mg) for the primary endpoint (mean WASO): the alternative hypothesis was that there was a difference. The two-sided type-I error limit was 0.05 and the type-II error limit was 0.10. A sample size of 70 patients provided 90% power to detect a > 20-minute difference in mean WASO between almorexant and placebo groups using a two-sided paired t test with a standard deviation for group difference of 50 minutes. Additional patients were included to allow for patient dropout.
The main analysis on the primary endpoint was based on the per-protocol (PP) set, comprising all-randomized patients without a major protocol deviation and who had five evaluable assessments (at least one PSG for each period). The analysis was performed using a linear fixed-effects model with treatment, period, and patient as covariates. Least-squares (LS) mean estimates of treatment effects versus placebo, associated two-sided 95% confidence intervals (CI), and parametric p values were determined. Data from almorexant dose groups were tested hierarchically in the order: 200, 100, 50, and 25 mg, with superiority concluded if differences favored almorexant at the 5% significance level. Sensitivity analyses based on the all-randomized set (ie, all-randomized patients) were also performed using ranked scores as the outcome of the linear model. First-order carry-over was tested using a linear fixed-effects model with patient, period, treatment, and carry-over as covariates.
Secondary and exploratory efficacy endpoints were analyzed in the same manner as the primary endpoint. If the primary endpoint achieved statistical significance, secondary endpoints for the same dose were analyzed in the order: TST then LPS.
Safety and other variables were summarized descriptively based on the safety set (ie, all enrolled patients who were randomized, received at least one dose of study treatment, and had at least one post-baseline safety assessment).
RESULTS
Patients and Disposition
A total of 242 patients were screened at 18 centers in the United States between 12th December 2007 and 4th April 2008, and 112 were randomized for treatment. Patient disposition is summarized in Figure 1 . In total, 103 evaluable patients received at least one dose of study medication during each of the five double-blind treatment periods, and were included in the PP set.
The majority of patients in the PP set were female (71%) and Caucasian (78%) ( Table 1 ). The mean age was 72.1 years, with 25% of patients aged >75 years. Mean BMI was 26.5 kg/m 2 (range 18.9-34.0 kg/m 2 ). The mean time since onset of insomnia was 13.5 years (range 0.3-65.5 years).
Primary Efficacy Endpoint
Almorexant had a dose-related treatment effect on WASO (Figure 2 Exploratory assessment of mean WASO by quarter of the night revealed beneficial treatment effects over each quarter of the night with almorexant 200 and 100 mg, during the second and third quarters with almorexant 50 mg, and during the third quarter with almorexant 25 mg. Almorexant 200 mg was also associated with a shorter mean WASO each hour compared with placebo (Supplementary Figure S1) .
Secondary Efficacy Endpoints
Dose-related increases in mean TST were observed (Figure 3) For both secondary endpoints, results from the analysis using the all-randomized set were consistent with the main analysis on the PP set. Post hoc subgroup analyses showed generally similar results in male and female patients. As for the primary efficacy endpoint, no period or carry-over effects were seen.
Exploratory Efficacy Endpoints
Subjective Sleep Assessments
Patient-reported measures of sleep showed dose-related changes and were generally consistent with PSG findings. Mean self-reported TST, quality of sleep, and depth of sleep were significantly greater, and time to fall asleep and wake time during sleep were shorter, with almorexant 200 and 100 mg versus placebo (Table 2) . Self-reported TST was also improved with almorexant 50 mg.
Next-Day Effects and Performance
Next-day morning performance and alertness measures (mean sleepiness, daytime alertness, total mood disturbance from the POMS, and the numbers of symbols completed correctly on the DSST) following almorexant treatment were comparable with placebo, except for a higher morning sleepiness scale with almorexant 200 mg (Table 3) . Figure S4) . A shorter latency to S2 was observed with almorexant 200 and 25 mg only, and no difference was observed in latency to S1 or SWS at any dose.
Sleep Architecture
Safety and Tolerability
The incidence of any AEs with almorexant (9.3%-11.3%) was similar to placebo (12.1%). Treatment-emergent AEs recorded in ≥1 patient per treatment group in the Safety set are shown in Table 4 . Somnolence was the most frequently reported AE (1%-4%) during almorexant treatment: it did not occur with placebo. All cases of somnolence in almorexant-treated patients were considered by treating physicians as related to study treatment, but the incidence of this AE was not dose-related. Other AEs (eg, headache, diarrhea) had similar incidences among treatments or were reported only occasionally, and most were mild with no evident relationship to almorexant dose.
Treatment-emergent orthostatic hypotension occurred in 9%-11% of patients across all doses, including placebo, and was asymptomatic in all but one case: no dose relationship was apparent regarding almorexant dose, and no relationship to study medication was reported by the treating physicians. One female patient experienced dizziness along with several other AEs (pollakiuria, urinary incontinence, gait disturbance, and nausea) 2.5 hours after the first dose of almorexant 200 mg. As a result this patient was discontinued from the study, these AEs were not considered related to study medication, and all resolved without clinical sequelae.
There were no deaths during the study. One SAE (pain in extremity on placebo) was reported. One patient experienced mild, transient muscular weakness in the knees and jaw within 8.5 hours of the second dose of almorexant 200 mg during the second double-blind treatment period, which had no emotional trigger and resolved completely without treatment; the subject continued in the study as planned. Six patients were prematurely discontinued due to an AE; three following treatment with almorexant 200 mg. None of the AEs that led to premature discontinuation were reported more than once, and all of them resolved without sequelae. There was no apparent pattern in the nature of recorded AEs.
Decreased neutrophil counts were reported in five subjects during the third or fourth treatment period while on placebo (n = 2) or almorexant 25 mg (n = 3). In four of these patients, later assessments showed a return to baseline or at least an improved neutrophil count: the fifth patient had no later assessment as he was discontinued due to positive urine drug screen findings. One subject showed elevations in both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) on Day 31 during the last treatment period (on placebo); follow-up checks during safety monitoring showed normal values by Day 53, and other liver function tests remained normal and stable. Marked increases in potassium in one patient, and in potassium and urea nitrogen in another patient were observed, but were only isolated observations. Vital signs, ECG variables, and hormone concentrations did not show any clinically meaningful changes during almorexant treatment.
DISCUSSION
This study was designed to determine the effective dose range of almorexant for decreasing WASO (primary endpoint), increasing TST, and reducing LPS, to evaluate effects on nextday measures, and to assess the safety and tolerability of almorexant in elderly patients with primary insomnia. Dose-related improvements in PSG sleep measures, including WASO and TST, were observed. Statistically significant reductions in mean WASO with the 200 and 100 mg doses were greater than 20 minutes, which is considered a clinically-relevant treatment effect as PP. Mean TST was also significantly increased with almorexant 200, 100, 50, and 25 mg in a dose-related manner. In addition, LPS was shorter with almorexant, but only statistically significantly so with the 200 mg dose.
Improvements in patient-reported sleep measures were generally consistent with PSG measures with almorexant 200 and 100 mg. Patient-reported TST, wake time during sleep, time to fall asleep, depth of sleep and quality of sleep were all improved. No significant effects were seen in terms of DSST scores, POMS assessments, or ratings of daytime alertness or ability to function. Further, the increased duration of TST was not sleep stage specific because the duration of each sleep stage rose in a dose-related manner. As would be expected with a DORA, the proportion of TST spent in REM sleep increased and the mean latency to REM decreased.
The current data extend findings from the almorexant dose-finding study in non-elderly patients, which demonstrated a significantly higher sleep efficiency following single doses of almorexant 400 mg versus placebo, and statistically significant, dose-related reductions in WASO at 400, 200, and 100 mg doses. 26 The doses of almorexant selected for elderly patients in this study were based on a dose-finding study in non-elderly subjects and earlier, Phase I trial findings. 22, 24, 26 A sedative effect was observed in healthy young adults (aged 18-32 years) at doses ≥ 200 mg, and in healthy elderly subjects (aged 64-81 years) at doses ≥ 100 mg, which suggested that lower doses might be effective in elderly patients with primary insomnia. Consequently, almorexant 25 mg was selected as the lowest dose in order to identify the minimum effective dose, and 200 mg was selected as the highest dose, taking into account higher exposure in elderly patients due to longer terminal elimination half-life. Almorexant was well tolerated in adults with primary insomnia receiving 400 mg, and in healthy young adults administered up to 1000 mg/d for 6 days.
The present study and earlier published data 26 suggest that almorexant produces atypical changes in sleep stages relative to GABAergic hypnotics. Similar to previous data with the dual orexin antagonist, SB-649868, almorexant consistently increased the amount of total time spent in REM and reduced latency to REM. 
